General Information of Drug (ID: DMIM1U9)

Drug Name
Vorolanib Drug Info
Synonyms
UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 2 [1]
Cross-matching ID
PubChem CID
59215954
CAS Number
CAS 1013920-15-4
TTD Drug ID
DMIM1U9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [3]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [4]
KH-902 DM8VO16 Diabetic macular edema 9B71.02 Phase 3 [5]
ABP 938 DM00ACQ Neovascular age-related macular degeneration 9B78.3Z Phase 3 [6]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [8]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [4]
BFH-772 DMVUX1C Psoriasis vulgaris EA90 Phase 2 [9]
ASP-8477 DMBZQS7 Neuropathic pain 8E43.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [11]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [12]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [3]
CT-102 DMB8PF3 Diabetic foot ulcer BD54 Approved [13]
Trapidil DMY67U8 Acute coronary syndrome BA41 Phase 4 [14]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [11]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [11]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [15]
PMID25623274-Compound-WO2014132220C2 DMXEZWP Pulmonary arterial hypertension BB01.0 Patented [16]
PMID25623274-Compound-WO2014132220C1 DMA2IMQ Pulmonary arterial hypertension BB01.0 Patented [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [2]
Vascular endothelial growth factor receptor (VEGFR) TTVJ1D8 NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
2 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
6 Clinical pipeline report, company report or official report of Amgen
7 National Cancer Institute Drug Dictionary (drug id 452042).
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 CA patent application no. 841416, Method of selecting therapeutic indications.
10 ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
11 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
12 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
13 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
14 Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
15 National Cancer Institute Drug Dictionary (drug id 695817).
16 Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.